Arcutis Biotherapeutics, Inc. (ARQT) NASDAQ
21.48
+0.0434(+0.20%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
21.48
+0.0434(+0.20%)
Currency In USD
| Previous Close | 21.44 |
| Open | 21.45 |
| Day High | 21.59 |
| Day Low | 21.15 |
| 52-Week High | 31.77 |
| 52-Week Low | 12.72 |
| Volume | 368,692.3 |
| Average Volume | 1.54M |
| Market Cap | 2.69B |
| PE | -1,074.17 |
| EPS | -0.02 |
| Moving Average 50 Days | 22.63 |
| Moving Average 200 Days | 23.44 |
| Change | 0.04 |
Arcutis Announces Publication of Positive Long-Term Safety and Efficacy Data with ZORYVE® (roflumilast) Cream 0.05% for Treatment of Mild-to-Moderate Atopic Dermatitis in Children Ages 2–5 in Pediatric Dermatology
GlobeNewswire Inc.
Mar 10, 2026 1:00 PM GMT
ZORYVE cream 0.05% was safe and well-tolerated, with efficacy that was maintained and improved over time up to 56 weeks of treatmentChildren ages 2-5 who achieved disease clearance and who switched to proactive twice-weekly application sustained dise
Arcutis Announces Promotion of Mas Matsuda to Executive Vice President and Chief Legal Officer to Support Next Phase of Growth
GlobeNewswire Inc.
Mar 05, 2026 2:00 PM GMT
WESTLAKE VILLAGE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the promotio
Arcutis Begins Enrolling Phase 1a/1b Study Evaluating ARQ-234, a CD200R Agonist, in Healthy Volunteers and Adults With Atopic Dermatitis
GlobeNewswire Inc.
Mar 03, 2026 1:00 PM GMT
Phase 1a/1b, first-in-human study to evaluate safety and tolerability for investigational ARQ-234 in healthy volunteers and adults with moderate to severe atopic dermatitisARQ-234 is a potent fusion-protein agonist of the CD200 receptor (CD200R), an